HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Pharmacokinetics of KRN 8602 in cancer patients].

Abstract
The pharmacokinetic properties of KRN 8602, an anthracycline compound, was studied by HPLC following intravenous administration of KRN 8602 to cancer patients. The results were as follows. (1) The plasma concentration-time curve declined as a triphasic function (alpha, beta, gamma) (t1/2 (alpha) = 0.02910, +/- 0.0054 hr, t1/2 (beta) = 0.704 +/- 0.319 hr, t1/2 (gamma) 8.37 +/- 1.37 hr). The blood cell concentration was higher than that in plasma. (2) The distribution volumes of the tissue compartment were larger than those of the central compartment. This result suggested that KRN 8602 would be easily transferred into the tissues. (3) The area under the curve (AUC) of KRN 8602 increased in proportion to the increase of dosage. (4) The metabolites of KRN 8602 were detected in plasma, blood cell and urine. (5) Urinary excretion of KRN 8602 and its metabolites were extremely low.
AuthorsH Majima, H Shinkai
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 18 Issue 15 Pg. 2589-95 (Dec 1991) ISSN: 0385-0684 [Print] Japan
PMID1746971 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Antibiotics, Antineoplastic
  • morpholinoanthracycline MX2
  • Carubicin
Topics
  • Adult
  • Antibiotics, Antineoplastic (administration & dosage, pharmacokinetics)
  • Breast Neoplasms (drug therapy, metabolism)
  • Carubicin (administration & dosage, analogs & derivatives, pharmacokinetics)
  • Drug Evaluation
  • Female
  • Humans
  • Infusions, Intravenous
  • Middle Aged

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: